Human immunodeficiency virus (HIV)-infected subjects mount a vigorous antigen-specific cytotoxic cellular immune response that is readily detectable in unstimulated peripheral blood mononuclear cells (PBMC) of many seropositive subjects (reviewed in [1D. By use of chromium release assays for the measurement of cytotoxic activity, it was reported that lysis of cells presenting the envelope glycoprotein occurred in both a major histocompatibility complex (MHC)-restricted and a non v Ml-Kl-restricted fashion [2, 3] . We recently demonstrated that a significant portion of the MHC-unrestricted cytolysis of envelope-expressing cells in vitro involved CD4 T lymphocytes, was related to cell-to-cell fusion, and resulted in lysis of both infected and uninfected CD4 T cells. In contrast to antigen-specific T cell~mediated lysis, this cytotoxicity was independent of extracellular calcium [4] .
To address the issue of whether this cytotoxicity could contribute to envelope glycoprotein-directed cytolysis detectable in HIV-infected persons, we examined unstimulated and in vitro-stimulated PBMC and CD4 and CDS T cells from HIV-I-infected donors for envelope glycoprotein-vdirected nonspecific cytotoxic activity and compared this cytotoxicity with antigen-specific cytotoxic T lymphocyte (CTL) responses in these subjects.
Material and Methods
Patient population. Six HIV-1 seropositive patients from the Medical Policlinic and the Department of Internal Medicine (Wurzburg University Medical School) were enrolled in this study. Their clinical characteristics and laboratory parameters at the time of the study were as follows: subject 9502: 31 years old, female, CDC group AI, CD4 cell count 625/mm 3 ; subject 9503: 31 years old, Three HIV-seronegative laboratory workers were recruited as controls.
Preparation ofeffector cells. PBMC were derived from blood by density-gradient centrifugation. Unstimulated polyclonal CD4 and CDS T lymphocyte populations were prepared by removal of cells of the unwanted phenotype (negative selection) using antibody-covered immunomagnetic beads (Dynal, Hamburg, Germany) and contained >SO% CD4 or CDS cells, respectively. For the preparation of stimulated polyclonal CD4 and CDS lymphocyte populations, cells were prepared by positive selection of cells expressing the relevant phenotype using antibody-covered immunomagnetic beads (Dynal). Cells were stimulated in vitro with 0.1 lJ.g/mL anti-CD3 monoclonal antibody (MAb) 12F6 and 100 U/ mL recombinant interleukin-2 in the presence of allogeneic irradiated (30 Gy) feeder cells for 1-3 weeks; stocks of stimulated cells contained >95% CD4 or CDS cells at the time of the experiments. At no time were cells exposed to exogenous viral antigen in vitro.
Preparation of target cells. Autologous Epstein-Barr virustransformed B lymphoblast cell lines (B-LCL) were infected with recombinant vaccinia virus constructs derived from HIV -l lI1B expressing either the complete (vPE 16) or a truncated envelope glycoprotein (vPE 17, which lacks the intracellular portion of gp41) [5] , the HIV-l gag/p55 protein (vAbT 141, coding for the HIV-I p55 gag gene product) [6] , or a control protein (Escherichia coli ,B-galactosidase, vSCS) [7] . B-LCL were infected at an MOl of 5-10 pfu/cell and incubated for 16 h at 37°C. Vaccinia virus infection and expression of the envelope glycoprotein were regularly monitored by flow cytometry using a human anti-vaccinia antiserum and anti-gp 120 MAb 902 [S] . HIV -I envelope glycoprotein was expressed in SO%-90% of the cells, and the level of vaccinia virus expression at the time of the experiments was comparable for all constructs.
Cytotoxicity assay. Standard chromium release assays were done as described previously [9] . Briefly, B-LCL were labeled with SO-lOO IJ.Ci ofNa251Cr04 for 60 min and added to unlabeled effector cells. Cells were incubated together for 7 h, and supernatants were harvested and counted in a gamma counter. Samples were tested in duplicate. Percent specific lysis was determined from the following formula: 100 X [(experimental release -spontaneous release)/(maximum release -spontaneous release)]. Maximum chromium release was determined by lysis of cells in 1.5% Triton X-IOO. The effector-to-target cell ratio ranged from 60:1 to 7: 1, unless otherwise indicated. Cytotoxicity assays were done in the absence and presence of 1.5 mM EDTA. To control for toxicity by EDTA, spontaneous chromium release values were determined in the presence and absence of EDT A. Spontaneous chromium release was <300;() for all target cell preparations except for cells treated with EDTA, for which it was <35%.
Flow cytometry. For determination of the T cell phenotype, cells were stained with fluorescein isothiocyanatc-conjugated anti-CD4, phycoerythrin-conjugated anti-CDS, and phycoerythrin Cy5-conjugated CD3 MAbs (Dako, Hamburg, Germany). Expression of the surface molecules was determined by flow cytometry (FACScan; Becton Dickinson, Mountain View, CA). ' C from seropositive subjects. PBMC were derived from asymptomatic HIV -seropositive subjects and separated into CD4 and CD8 T cell populations. These cells were then used as effector cells in cytotoxicity assays. PBMC from seronegative persons were used as control effector cells. Target cells were autologous B-LCL infected with recombinant vaccinia viruses expressing either the HIV-I gag protein or the HIV-l envelope glycoprotein. B-LCL infected with a vaccinia vector coding for an irrelevant protein served as a control. Expression of virus protein was monitored by flow cytometry and was comparable for all targets in each assay. Figure 1 shows representative data from 3 seropositive persons and a seronegative control donor. HIV antigen-presenting autologous cells were lysed by unstimulated PBMC from all of these subjects. Similarly, CD4 T cells from all subjects lysed envelope glycoprotein -expressing cells. Envelope glycoprotein-directed lysis involving CD4 T cells was observed in both the absence and presence of EDTA, indicating nonspecific cytotoxicity related to cell-to-cell fusion. No antigen-specific calcium-dependent cytolytic response mediated by CD4 T cells was detected in the infected patients. In addition, CD8 T cello. mediated lysis of envelope glycoprotein-and gag protein expressing cells was observed in HIV-infected subjects 9503 and 9505. In contrast to the toxicity involving CD4 T cells, envelope glycoprotein-directed lysis exerted by CD8 T cells was calcium-dependent, indicating classical antigen-specific CTL activity.
Results

HIV-I-directed cytotoxic response in unstimulated PbM
The results obtained using unfractionated PBMC from the 3 seropositive subjects shown in figure 1 represent three different cytotoxicity response patterns. For instance, PBMC from subject 9503 exhibited both antigen-specific CD8 CTL activity and nonspecific envelope-directed lysis involving CD4 T cells. In contrast, PBMC from subject 9502 contained no antigenspecific cytolysis but a significant level of nonspecific cytotoxicity. In addition, unfractionated PBMC from subject 9505 exhibited antigen-specific cytotoxicity directed at gag and envelope targets but no CD4 T cell-mediated calcium-independent toxicity. However, after fractionation, CD4 cells from this individual exhibited calcium-independent envelope-directed lysis. The inability to demonstrate nonspecific envelope glycoprotein -directed lysis using PBMC from this subject reflects the low CD4 cell number in the peripheral blood of this particular donor.
HIV-I gag-and envelope-directed cytotoxicity in stimulated T cells. Having demonstrated the presence of both antigenspecific CD8 T cell-mediated cytotoxicity in unstimulated PBMC of HIV-infected subjects and nonspecific envelope-directed lysis involving CD4 cells from both seropositive and seronegative persons, we examined in vitro-stimulated cells from these and several additional subjects. Seven PBMC samples from 6 HIV-I-seropositive subjects and 3 specimens from 3 seronegative control donors were tested. CDS cells from infec ted but not control donors exerted gag-and enve lopespeci fic cytotoxicity. In addition, simi lar to what has been observed us ing unstimu lated ce lls, en velope glycoprotein~di-recte d cyto tox icity was detectable in PBMC and CD4 cells from both seropositive and seronegative subject s. In con tras t to envelope-specific lysis exerted by CDS CTL , cyto tox icity invo lving CD4 ce lls was ind epend ent o f extracell ular calci um (figure 2). Mo reover, lysis of envelope-expressing ce lls by CD4 cells was maintained when heterologous targe t cells were used, whereas CDS CTL -mcdiated lys is was res tricted to auto logo us ce lls (data not shown). No antige n-s pec ific calc ium-depende nt cyto lytic activity mediated by CD 4 ce lls was detectable.
Discu ssion
The Hl Y-specific cyto lytic immune response mediated by CD8 CTL has been extens ively examined in infected persons.
In most studies, cytotoxic activity was assessed by chromium release assay using, as target cells, autologous or HLA-matched B cells, eit her infected with recombinant vaccinia viruses coding for H IV pro teins or sensitize d wit h synthetic v ira l peptides (reviewed in [I ] ). Lysis of target ce lls presenting the envelop e glycoprotein was regarded as unique because it occ urred in both an MHC-restricted and MHC-unrestrict ed fas hio n [2] . We recently demonstrated that rapi d lysis of HTV-infected and envelope glycoprotein-expressing ce lls occurs in vitro in the presence of primary CD4 T ce lls. Although this cytolys is rcsembled antigen-specific cytotoxicity in the chromium release assay, it was MHC-unrestricted, independent of ext race llular calciu m, and appeared to be related to cell -to-cel l fusion . It may therefore represent rapi d disi ntegration of the ce ll fusio n event [4] .
On the basis of this observation, we evaluated the co ntribution of cytotox ic act iv ity exerted by both mechanisms in PBMC Figure 2 . H1V-1 gag-and envelope-directed cytotoxicity in stimulated T cells from seropositive and seronegative subjects. In vitro stimulated peripheral blood mononuclear (ells (PBMC) and CDS and CD4 T cells from 6 seropositive (7 specimens, A) and 3 seronegative (8) subjects were used as effector cells in chromium release assays using autologous HlV-I gag (VV/gag) or envelope glycoprotein (vPEI7; VV/env) expressing B lymphoblasts as target cells. % lysis of control target cells was subtracted before lysis values of gag-and envelope-expressing cells was plotted. Specific lysis values < 10% were regarded as insignificant. Effector-to-target cell ratio was 90 ; I; incubation time was 7 h. from infected persons. The data demonstrate that, in addition to antigen-specific CDS CTL-mediated lysis of target cells, cytotoxicity involving envelope glycoprotein -sexpressin g cell s and CD4 T cells was readily detectable in the blood of HrVinfected subjects, using both unstimulated and in vitro -stimulated cells. Moreover, whereas antigen-specific CDS ceIl -mediated lysis of envelope target cells was detected in only some HIV-infected subjects, nonspecific cytotoxicity was detectable in all donors. Similar results were obtained using either the complete recombinant vaccinialHIV-I envelope viru s vPE 16 or the truncated envelope construct vPEI7, although lysis of vPE 16-infected cells by CD4 cells was frequently less pronounced due to the reduced surface expression of the glycoprotein when this construct is used. The inability to detect nonspecific envelope-directed lysis in unfractionated PBMC from seropositive donors with low CD4 T cell numbers and the fact that this type of toxicity is observed in CD4 T cells from these donors after separation indicate that a low CD4:CDS T cell ratio in the blood may mask this type of cytotoxicity. No antigen-specific calcium-dependent cytolytic activity mediated by CD4 T lymphocytes was detected in the persons examined, This ob serv ation confirms reports by others (reviewed in [I] ).
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Previous reports suggested that non-MHC-restricted killing of envelope glycoprotein-expressing cell s by PBMC was being mediated predominantl y by NK and kill er cells, which are armed with cytophilic antibodies [10] [11] [12] . Although cytolysis mediated by these killer cells was not specifically addresscd in the present study, our results suggest that a significant portion of all envelope-directed cytol ysis exerted by PBMC ex vivo could be attributed either to CDS CTL or to nonspecific fusionrelated lysis involving primary CD4 T cells.
Recognition and lysis by antigen-specific CTL require presentation of viral peptides in the context of MHC molecules. In contrast, fusion-related cytotoxicity needs expression of the nat ive glycoprotein on the surface of infected cells. Therefore, since expression of the glycoproteins occurs at a later stage of viral replication, antigen-specific lysis mediated by CDS CTL may to some extent precede cell-to-cell fusion toxicity in vivo. However, there is ample evidence indicating that target cells relevant for CD4 T cell fusion are present in the infected tissue.
For instance, the intracellular life cycle of HIV is relatively short and the interval between translation of early virus antigens and expression of the envelope glycoprotein may be only a few hours [13] . In addition, large numbers of virions are present in the serum of infected subjects and argue against efficient elimination of infected cells before viral synthesis has been completed [13, 14] . Moreover, fusion of viral and cellular membranes may render HIV -infected cells as targets for fusionrelated cytolysis even before viral replication has taken place because envelope glycoproteins present in the HIV membrane become, though only for a limited time, part of the cell surface [ 15] .
It is assumed, because the HIV -specific CTL response is exceptionally vigorous, that lysis of HI V-infected cells by CDS CTL is relevant in the infected individual. In this study, the extent of cytotoxicity directed at HIV antigen-expressing cells exerted by CDS CTL and CD4 T cells was in a similar range. Therefore, the similarity of the results obtained using an identical assay protocol for lysis involving CDS CTL and CD4 T cells would suggest that nonspecific, CD4 T cell-involving cytotoxicity might contribute to lysis of infected cells in vivo.
In conclusion, both antigen-specific CDS CTL-mediated cytotoxicity directed at multiple HIV antigens and fusion-related lysis of envelope glycoprotein-expressing cells involving CD4 T cells constitute the main components of cytotoxicity observed in PBMC from infected persons. Both factors may contribute to the destruction of virus-infected CD4 T cells in the infected individual.
